Taisho Pharmaceutical Holdings

Taisho Pharmaceutical Holdings is a prominent manufacturer of specialty and generic drugs, primarily focused on the production and sale of self-medication products. The company's portfolio includes a variety of well-known items, such as cold medicines, allergy medications, and dietary supplements like the Lipovitan and Pabron series. Operating through two main segments—Self-Medication and Prescription Pharmaceuticals—Taisho derives the majority of its revenue from the Self-Medication segment, catering primarily to external customers in Japan. The company also explores mergers and acquisitions as a strategy to enhance its research, development, manufacturing, and marketing capabilities.

Akira Uehara

Chairman, President and CEO

10 past transactions

Biolinq

Series C in 2025
Founded in 2012, Biolinq develops digital health platforms centered around skin-applied electronic biosensors. These minimally invasive sensors analyze biomarkers in interstitial fluid to provide real-time, actionable health information, initially focusing on continuous glucose monitoring for diabetic patients.

Biolinq

Venture Round in 2024
Founded in 2012, Biolinq develops digital health platforms centered around skin-applied electronic biosensors. These minimally invasive sensors analyze biomarkers in interstitial fluid to provide real-time, actionable health information, initially focusing on continuous glucose monitoring for diabetic patients.

VIE STYLE

Series A in 2024
VIE STYLE offers wearable music device and AI technology services.

AuB

Series C in 2022
Founded in Japan in 2015, AuB specializes in developing supplements, foods, and beverages designed to enhance the intestinal environment of athletes. The company's products are based on research into microbiome and stool samples from athletes, aiming to improve performance and overall human health.

Biolinq

Series B in 2021
Founded in 2012, Biolinq develops digital health platforms centered around skin-applied electronic biosensors. These minimally invasive sensors analyze biomarkers in interstitial fluid to provide real-time, actionable health information, initially focusing on continuous glucose monitoring for diabetic patients.

Moodify

Series A in 2021
Moodify develops an AI-powered platform for designing fragrances. Harnessing advanced machine learning techniques and neuroscience research, Moodify enables brands to create scalable, compliant, and sustainable fragrance formulas efficiently.

aiwell

Series A in 2020
aiwell Inc. is a Tokyo-based company focused on the research and development of AI proteomics, which involves the analysis of protein changes in living organisms to detect signs of health conditions. The company's platform digitizes proteins from humans and livestock, facilitating sample processing, small-volume analysis, and comparative imaging. aiwell offers innovative solutions, including aiwell care, a micro blood sampling kit that enables users to conduct blood tests at home. Furthermore, it provides AI-driven support for diagnosis, drug discovery, and remote medical care. The company collaborates with the Tokyo Institute of Technology to advance its research initiatives. aiwell Inc. was established in 2018 and was formerly known as CF Partners Co., Ltd.

Nanotis

Series A in 2020
Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices aimed at addressing challenges in infectious disease testing, particularly for influenza. The company manufactures microchip-based devices that allow users to quickly and accurately diagnose illnesses. By providing early diagnosis solutions, Nanotis supports medical professionals in practical healthcare settings, thereby enhancing the efficiency of healthcare delivery and improving patient outcomes.

Quantum Operation

Corporate Round in 2020
Founded in Tokyo, Japan in 2017, Quantum Operation specializes in developing innovative IoT sensors tailored for medical and nursing industries. Its flagship product is a wearable device designed to improve blood glucose monitoring for diabetes management.

UPSA SAS

Acquisition in 2018
UPSA SAS is a company focused on addressing pain and self-medication through its range of products. It manufactures over-the-counter medicines aimed at various health issues, including flu, vitality, digestion, and sleep quality. The company offers pharmaceuticals, food supplements, and medical devices designed for patients of all ages, from infants to seniors. By providing these products, UPSA SAS aims to support both consumers and pharmacists in managing everyday health challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.